Key result
Inoculation of tamarin monkeys with a recombinant vaccinia virus expressing HAV structural polypeptides induced a specific anti-HAV immune response protective against virulent HAV challenge.
Why the study?
Does a recombinant vaccinia virus expressing HAV structural polypeptides induce a protective immune response against HAV in tamarin monkeys?
Does a recombinant vaccinia virus expressing HAV structural polypeptides induce a protective immune response against HAV in tamarin monkeys?
A recombinant vaccinia virus expressing HAV structural polypeptides provides protective immunity in a non-human primate model, demonstrating potential as a vaccine candidate.
Should not inform clinical HAV prevention; leaves open vaccinia-based expression systems for further antigen research.
A recombinant vaccinia virus containing most of the P1 region of hepatitis A virus (HAV) was constructed. Cell lysates of cultures infected with the virus contained HAV proteins detectable by radioimmunoassay. Western blot analysis revealed the presence of a single protein of Mr 60K to 62K, bearing epitopes from structural polypeptides VP4, -3 and -2, and the N terminus of VP1. The size of the protein suggests that at least some of the vaccinia virus thymidine kinase is also expressed. Inoculation of tamarin monkeys with the recombinant virus resulted in the development of a specific anti-HAV immune response which was protective against challenge with a virulent strain of HAV. Recombinant viruses expressing the above region of HAV or the proteins expressed by such viruses may be useful in the development of a vaccine suitable for use in man.
No takes yet. Share an insight, caveat, or question.
Karayiannis et al. (1991) studied Hepatitis A. Recombinant vaccinia virus expressing hepatitis A virus structural polypeptides was evaluated on Specific anti-HAV immune response and protection against virulent HAV challenge. Inoculation of tamarin monkeys with a recombinant vaccinia virus expressing HAV structural polypeptides induced a specific anti-HAV immune response protective against virulent HAV challenge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: